A Closer Look at CRISPR Therapeutics's Options Market Dynamics - CRISPR Therapeutics (NASDAQ:CRSP)

Financial giants have made a conspicuous bearish move on CRISPR Therapeutics. Our analysis of options history for CRISPR Therapeutics (NASDAQ:CRSP) revealed 19 unusual trades.

Delving into the details, we found 42% of traders were bullish, while 57% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $271,080, and 12 were calls, valued at $457,480.

What's The Price Target?

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $105.0 for CRISPR Therapeutics over the last 3 months.

Analyzing Volume & Open Interest

In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 1195.07 with a total volume of 2,296.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for CRISPR Therapeutics's big money trades within a strike price range of $50.0 to $105.0 over the last 30 days.

CRISPR Therapeutics Option Activity Analysis: Last 30 Days

Biggest Options Spotted:

Symbol	PUT/CALL	Trade Type	Sentiment	Exp. Date	Strike Price	Total Trade Price	Open Interest	Volume
CRSP	CALL	TRADE	BULLISH	01/17/25	$60.00	$82.5K	502	61
CRSP	PUT	TRADE	NEUTRAL	12/15/23	$65.00	$67.1K	1.8K	403
CRSP	CALL	TRADE	BULLISH	01/16/26	$105.00	$51.2K	8	40
CRSP	PUT	SWEEP	BEARISH	12/15/23	$63.00	$46.2K	385	57
CRSP	CALL	TRADE	BULLISH	01/19/24	$60.00	$43.4K	4.2K	477

About CRISPR Therapeutics

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

In light of the recent options history for CRISPR Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.

Present Market Standing of CRISPR Therapeutics

Currently trading with a volume of 6,643,464, the CRSP's price is down by -2.74%, now at $62.77.
RSI readings suggest the stock is currently may be approaching overbought.
Anticipated earnings release is in 71 days.

Expert Opinions on CRISPR Therapeutics

Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $95.0.

An analyst from Truist Securities downgraded its action to Buy with a price target of $220.
Maintaining their stance, an analyst from Morgan Stanley continues to hold a Underweight rating for CRISPR Therapeutics, targeting a price of $42.
An analyst from JMP Securities has revised its rating downward to Market Outperform, adjusting the price target to $74.
Reflecting concerns, an analyst from Mizuho lowers its rating to Buy with a new price target of $82.
Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on CRISPR Therapeutics with a target price of $57.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for CRISPR Therapeutics, Benzinga Pro gives you real-time options trades alerts.

CRSPCRISPR Therapeutics AG

$51.370.29%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.